Wednesday, October 23, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Migraine is a complex, chronic disease that results in significant patient and economic burden. Migraine ranks second worldwide in terms of years lost due to disability. Direct annual all cause healthcare costs for a migraine patient is over twice that of a non-migraine patient. Indirect costs from the impact of the disease on a patient's ability to function (absenteeism and presenteeism) total over $35B annually.

It is important to treat an attack at the onset of symptoms since those symptoms can last up to 48 hours after the resolution of the headache and may include difficulty concentrating, feeling tired, and neck stiffness, among other symptoms.

One of the main goals of acute treatment of migraine is freedom from pain and associated symptoms without recurrence. It is therefore important that every person with migraine, regardless of migraine frequency, be offered a migraine specific treatment that has freedom from pain data, freedom from associated symptom data and evidence that the treatment can prevent a moderate to severe migraine attack.

The objective for this webinar is to review the migraine disease state and phases of a migraine attack, and outline clinical data as a treatment option for the acute treatment of migraine.

Learning Objectives

• Discuss the complexity of migraine disease and the burden of the disease as it relates to function.
• Discuss the treatment landscape, with a focus on a treatment option for acute treatment of migraine in adults.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.